Loading clinical trials...

Continuous Wearable Monitor for the Detection and Release of Freezing of Gait. | Clinical Trials | Clareo Health

COMPLETED

Continuous Wearable Monitor for the Detection and Release of Freezing of Gait.

NCT06385392•HealthPartners Institute

Summary

The proposed system (haptic module and insole device) for daily in-community use that detects the occurrence of freezing of gait (FOG) in people with Parkinson's disease (PD). and triggers external cueing stimuli to unfreeze the individual. The purpose of the overall Phase II study is to: (1) Develop a production ready system, (2) Develop a companion mobile app for the proposed system and refine previously developed FOG detection algorithms, and (3) Validate the proper operation of the system and demonstrate its efficacy through lab and in-community testing. This study will focus on validating the system and demonstrating efficacy through in-community testing.

Eligibility

Age

45 - 80 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Ability to provide and provision of signed and dated informed consent form.
•Age 45 or older
•Diagnosis of idiopathic PD, as determined by a movement disorders neurologist in accordance with the PD Society Brain Bank diagnostic criteria.
•Evidence of presence of freezing gait as a symptom. Determined from combination of clinical examination (observation of freezing) and New Freezing of Gait Questionnaire (NFOG).
•Able to complete a 2-minute walk test at the pre-treatment visit.
•Currently on a stable prescription medication regimen for PD and willing to adhere to the regimen during the study.
•Ability to don and doff the insole and haptic module independently or have daily assistance during the study intervention.

Exclusion Criteria

•Non-English speaking
•History of musculoskeletal disorders that significantly affect movement of lower limbs as determined at the time of enrollment.
•Other significant neurological disorders that may affect participation or performance in the study.
•Neuropathy at the ankle assessed at the pre-treatment visit using the haptic module.
•Hallucinations
•Non-ambulatory
•Legally Blind
•Symptomatic hypotension
•Any condition which would limit sensation in the legs or requires use of wraps, bandages or other items which may limit sensation in the legs (e.g., lymphedema) that would interfere with the performance of the haptic device, in the opinion of the investigator.

Locations (2)

Struthers Parkinson's Center

Golden Valley, Minnesota, United States

HealthPartners Neuroscience Center

Saint Paul, Minnesota, United States

Key Dates

Start Date

September 11, 2024

Primary Completion Date

April 28, 2025

Completion Date

April 28, 2025

Last Updated

June 22, 2025

Enrollment

ACTUAL participants

Conditions

Parkinson Disease

Interventions

Haptic module and insole device

DEVICE

[18F]F-DOPA Imaging in Patients With Autonomic Failure

NCT04246437

Autonomic FailurePure Autonomic Failure+3 more

View study

RECRUITINGNA

Characterizing the Pathophysiological Role of the Pallido-thalamocortical Motor Pathway in Parkinson's Disease.

NCT06692920

Parkinson Disease

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: June 22, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Continuous Wearable Monitor for the Detection and Release of Freezing of Gait.

Inclusion Criteria

Exclusion Criteria

[18F]F-DOPA Imaging in Patients With Autonomic Failure

Characterizing the Pathophysiological Role of the Pallido-thalamocortical Motor Pathway in Parkinson's Disease.

Montelukast in Parkinson Disease

Exercise for Cognitive Excellence in Parkinson's Disease

SAD Study in Patients With Parkinson's Disease and Motor Fluctuations

The Effect of Functional Rotational Exercises on Fall Risk and Mobility in Parkinson's Disease Patients